首页 > 最新文献

Journal of the Chinese Medical Association最新文献

英文 中文
An early report of exoscope-assisted otologic surgery. 外窥镜辅助耳科手术的早期报道。
IF 3 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-05-01 DOI: 10.1097/JCMA.0000000000000907
Bang-Yan Zhang, Valerie Wai-Yee Ho, Tzong-Yun Tsai, Kai-Chieh Chan

Background: Exoscope has been used in otoneurologic surgery in several reports. However, most ear surgeries are performed using either microscope or endoscopy today. The purpose of this study is to present our subjective and objective experience of using this instrument in our institution.

Methods: Sixteen ears with different severity and condition in 15 consecutive patients were enrolled. A questionnaire with 12 questions was sent to different participants, including surgeons, residents, medical students, and scrub nurses in the operation room. The total score and average score of each item were calculated and analyzed.

Results: Exclusive exoscopic operation was performed on 13 patients with 14 procedures. A combination of endoscopy-exoscope and microscope-exoscope was used in one patient, respectively. There were no complications. Hearing recovery or disease extirpation was achieved in most patients. Twenty participants in the operation room filled out the questionnaire. There was no significant difference between the different groups. High ratings were reported in terms of image quality, stereoscopic effects, magnification rate, and the same field of view as the surgeon. Worse ratings were reported in items related to limited working space, increase in eye strain by video observation, and focusing difficulty.

Conclusion: Exoscopic ear surgery is feasible, safe, and effective in managing various otologic conditions involving external ear, middle ear, mastoid, and lateral skull base. Its high-definition image quality, stereoscopic effects, sufficient magnification, reliability and teaching value made it a potential instrument in general ear surgeries. Further improvements to current drawbacks can be anticipated.

背景:外窥镜在耳神经外科手术中的应用已有几篇报道。然而,今天大多数耳部手术都是使用显微镜或内窥镜进行的。本研究的目的是呈现我们在本机构使用该仪器的主观和客观经验。方法:连续15例患者,16耳不同程度、不同状态。一份包含12个问题的调查问卷被发送给不同的参与者,包括外科医生、住院医师、医学生和手术室的清洁护士。计算并分析各题的总分和平均分。结果:对13例患者进行了14道手术方式的独家外直视手术。1例患者分别采用内窥镜-外窥镜和显微镜-外窥镜联合检查。没有并发症。大多数患者的听力恢复或疾病消失。手术室的20名参与者填写了调查问卷。不同组间无显著差异。在图像质量,立体效果,放大率和与外科医生相同的视野方面,报告了较高的评分。在与有限的工作空间、观看视频增加眼睛疲劳和聚焦困难相关的项目中,得分较低。结论:外耳镜手术治疗外耳、中耳、乳突和侧颅底等多种耳科疾病是可行、安全、有效的。其高清晰度的图像质量、立体感的效果、足够的放大倍率、可靠性和教学价值使其成为普通耳科手术的潜在仪器。可以预期对当前缺点的进一步改进。
{"title":"An early report of exoscope-assisted otologic surgery.","authors":"Bang-Yan Zhang,&nbsp;Valerie Wai-Yee Ho,&nbsp;Tzong-Yun Tsai,&nbsp;Kai-Chieh Chan","doi":"10.1097/JCMA.0000000000000907","DOIUrl":"https://doi.org/10.1097/JCMA.0000000000000907","url":null,"abstract":"<p><strong>Background: </strong>Exoscope has been used in otoneurologic surgery in several reports. However, most ear surgeries are performed using either microscope or endoscopy today. The purpose of this study is to present our subjective and objective experience of using this instrument in our institution.</p><p><strong>Methods: </strong>Sixteen ears with different severity and condition in 15 consecutive patients were enrolled. A questionnaire with 12 questions was sent to different participants, including surgeons, residents, medical students, and scrub nurses in the operation room. The total score and average score of each item were calculated and analyzed.</p><p><strong>Results: </strong>Exclusive exoscopic operation was performed on 13 patients with 14 procedures. A combination of endoscopy-exoscope and microscope-exoscope was used in one patient, respectively. There were no complications. Hearing recovery or disease extirpation was achieved in most patients. Twenty participants in the operation room filled out the questionnaire. There was no significant difference between the different groups. High ratings were reported in terms of image quality, stereoscopic effects, magnification rate, and the same field of view as the surgeon. Worse ratings were reported in items related to limited working space, increase in eye strain by video observation, and focusing difficulty.</p><p><strong>Conclusion: </strong>Exoscopic ear surgery is feasible, safe, and effective in managing various otologic conditions involving external ear, middle ear, mastoid, and lateral skull base. Its high-definition image quality, stereoscopic effects, sufficient magnification, reliability and teaching value made it a potential instrument in general ear surgeries. Further improvements to current drawbacks can be anticipated.</p>","PeriodicalId":17251,"journal":{"name":"Journal of the Chinese Medical Association","volume":"86 5","pages":"523-528"},"PeriodicalIF":3.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9880388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An open-label randomized noninferior study of generic name and brand name of propafenone for rhythm control in patients with paroxysmal atrial fibrillation. 一项开放标签随机非劣标研究:普罗帕酮用于阵发性心房颤动患者心律控制的通用名和品牌名。
IF 3 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-05-01 DOI: 10.1097/JCMA.0000000000000903
Chye-Gen Chin, Yu-Cheng Hsieh, Wei-Shiang Lin, Yenn-Jiang Lin, Chuen-Wang Chiou, Tsung-Hsien Lin, Chien-Lung Huang, Yuan Hung, Yung-Kuo Lin, Shih-Lin Chang, Tong-Chen Yeh, Hsiang-Chun Lee, Wen-Ter Lai, Ming-Hsiung Hsieh

Background: Propafenone is a class IC antiarrhythmic agent that is commonly used as the first-line therapy for patients with paroxysmal atrial fibrillation (AF) in Taiwan. This study compared the efficacy and safety of generic (Rhynorm) and brand name (Rytmonorm) propafenone for rhythm control of paroxysmal AF in Taiwan.

Methods: This was an open-label randomized multicenter noninferior study conducted in Taiwan. We enrolled 76 patients with AF. To investigate the efficacy of propafenone, we used a wearable electrocardiogram (ECG) event recorder to evaluate the daily burden of AF episodes in patients for 24 weeks. The primary efficacy endpoint was the frequency of AF with clinical significance, which was indicated by AF duration ≥30 seconds. The safety endpoints included proarrhythmic or hemodynamic adverse events.

Result: To analyze the efficacy and safety of these agents, 71 patients (five patients with screen failure) were randomized to two groups, specifically a Rhynorm group (n = 37) and a Rytmonorm group (n = 34), for 24 weeks of the treatment period. The baseline patient characteristics were comparable between the groups. However, the Rhynorm group was older (65.4 ± 8.40 vs 59.8 ± 10.8 years; p = 0.02). The primary efficacy endpoint at week 24 decreased by 4.76% ± 18.5% (from 24.3% ± 33.9% to 19.0% ± 28.7%; p = 0.13) in the Rhynorm group and by 3.27% ± 15.2% (from 16.9% ± 26.4% to 13.6% ± 19.2%; p = 0.22) in the Rytmonorm group, with an intergroup difference of 1.5% ± 17.0%; p = 0.71. This finding indicates that Rhynorm is not inferior to Rytmonorm ( p = 0.023 for noninferiority). The safety profile of the agents was comparable between the two groups.

Conclusion: Our results verified that Rhynorm was noninferior to Rytmonorm in terms of efficacy and safety for treating paroxysmal AF in Taiwan ( ClinicalTrials.gov Identifier: NCT03674658).

背景:普罗帕酮是一种IC类抗心律失常药物,在台湾常作为阵发性心房颤动(AF)患者的一线治疗药物。本研究比较仿制药(Rhynorm)与品牌药(Rytmonorm)普罗帕酮在台湾地区控制阵发性房颤心律的疗效与安全性。方法:这是一项在台湾进行的开放标签随机多中心非劣质研究。我们招募了76名房颤患者。为了研究普罗帕酮的疗效,我们使用可穿戴式心电图(ECG)事件记录仪来评估患者24周内房颤发作的每日负担。主要疗效终点为有临床意义的房颤发生频率,以房颤持续时间≥30秒为指标。安全性终点包括心律失常或血流动力学不良事件。结果:为分析这些药物的疗效和安全性,71例患者(5例筛查失败)随机分为两组,Rhynorm组(n = 37)和Rytmonorm组(n = 34),疗程为24周。两组患者的基线特征具有可比性。Rhynorm组年龄较大(65.4±8.40 vs 59.8±10.8);P = 0.02)。第24周的主要疗效终点下降了4.76%±18.5%(从24.3%±33.9%降至19.0%±28.7%;p = 0.13),比对照组低3.27%±15.2%(由16.9%±26.4%增至13.6%±19.2%;p = 0.22),组间差异为1.5%±17.0%;P = 0.71。这一发现表明Rhynorm并不劣于Rytmonorm(非劣效性p = 0.023)。两组药物的安全性具有可比性。结论:我们的研究结果证实,Rhynorm在台湾治疗阵发性房颤的疗效和安全性方面不逊于Rytmonorm (ClinicalTrials.gov标识号:NCT03674658)。
{"title":"An open-label randomized noninferior study of generic name and brand name of propafenone for rhythm control in patients with paroxysmal atrial fibrillation.","authors":"Chye-Gen Chin,&nbsp;Yu-Cheng Hsieh,&nbsp;Wei-Shiang Lin,&nbsp;Yenn-Jiang Lin,&nbsp;Chuen-Wang Chiou,&nbsp;Tsung-Hsien Lin,&nbsp;Chien-Lung Huang,&nbsp;Yuan Hung,&nbsp;Yung-Kuo Lin,&nbsp;Shih-Lin Chang,&nbsp;Tong-Chen Yeh,&nbsp;Hsiang-Chun Lee,&nbsp;Wen-Ter Lai,&nbsp;Ming-Hsiung Hsieh","doi":"10.1097/JCMA.0000000000000903","DOIUrl":"https://doi.org/10.1097/JCMA.0000000000000903","url":null,"abstract":"<p><strong>Background: </strong>Propafenone is a class IC antiarrhythmic agent that is commonly used as the first-line therapy for patients with paroxysmal atrial fibrillation (AF) in Taiwan. This study compared the efficacy and safety of generic (Rhynorm) and brand name (Rytmonorm) propafenone for rhythm control of paroxysmal AF in Taiwan.</p><p><strong>Methods: </strong>This was an open-label randomized multicenter noninferior study conducted in Taiwan. We enrolled 76 patients with AF. To investigate the efficacy of propafenone, we used a wearable electrocardiogram (ECG) event recorder to evaluate the daily burden of AF episodes in patients for 24 weeks. The primary efficacy endpoint was the frequency of AF with clinical significance, which was indicated by AF duration ≥30 seconds. The safety endpoints included proarrhythmic or hemodynamic adverse events.</p><p><strong>Result: </strong>To analyze the efficacy and safety of these agents, 71 patients (five patients with screen failure) were randomized to two groups, specifically a Rhynorm group (n = 37) and a Rytmonorm group (n = 34), for 24 weeks of the treatment period. The baseline patient characteristics were comparable between the groups. However, the Rhynorm group was older (65.4 ± 8.40 vs 59.8 ± 10.8 years; p = 0.02). The primary efficacy endpoint at week 24 decreased by 4.76% ± 18.5% (from 24.3% ± 33.9% to 19.0% ± 28.7%; p = 0.13) in the Rhynorm group and by 3.27% ± 15.2% (from 16.9% ± 26.4% to 13.6% ± 19.2%; p = 0.22) in the Rytmonorm group, with an intergroup difference of 1.5% ± 17.0%; p = 0.71. This finding indicates that Rhynorm is not inferior to Rytmonorm ( p = 0.023 for noninferiority). The safety profile of the agents was comparable between the two groups.</p><p><strong>Conclusion: </strong>Our results verified that Rhynorm was noninferior to Rytmonorm in terms of efficacy and safety for treating paroxysmal AF in Taiwan ( ClinicalTrials.gov Identifier: NCT03674658).</p>","PeriodicalId":17251,"journal":{"name":"Journal of the Chinese Medical Association","volume":"86 5","pages":"472-478"},"PeriodicalIF":3.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9882475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply to "The statistical significance may be misinterpreted". 回复“统计显著性可能被误解”。
IF 3 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-05-01 DOI: 10.1097/JCMA.0000000000000908
Yu-Wen Cheng, Yang-Yi Chen, Chien-Ju Lin, Yi-Ting Chen, Ann-Shung Lieu, Hung-Pei Tsai, Aij-Lie Kwan
{"title":"Reply to \"The statistical significance may be misinterpreted\".","authors":"Yu-Wen Cheng,&nbsp;Yang-Yi Chen,&nbsp;Chien-Ju Lin,&nbsp;Yi-Ting Chen,&nbsp;Ann-Shung Lieu,&nbsp;Hung-Pei Tsai,&nbsp;Aij-Lie Kwan","doi":"10.1097/JCMA.0000000000000908","DOIUrl":"https://doi.org/10.1097/JCMA.0000000000000908","url":null,"abstract":"","PeriodicalId":17251,"journal":{"name":"Journal of the Chinese Medical Association","volume":"86 5","pages":"535"},"PeriodicalIF":3.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9882481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Maternal factors associated with fetal macrosomia. 与胎儿巨大儿相关的母体因素。
IF 3 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-05-01 DOI: 10.1097/JCMA.0000000000000894
Chia-Hao Liu, Szu-Ting Yang, Peng-Hui Wang
{"title":"Maternal factors associated with fetal macrosomia.","authors":"Chia-Hao Liu,&nbsp;Szu-Ting Yang,&nbsp;Peng-Hui Wang","doi":"10.1097/JCMA.0000000000000894","DOIUrl":"https://doi.org/10.1097/JCMA.0000000000000894","url":null,"abstract":"","PeriodicalId":17251,"journal":{"name":"Journal of the Chinese Medical Association","volume":"86 5","pages":"455-456"},"PeriodicalIF":3.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9880386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The safety and cost-analysis of simultaneous versus staged bilateral total knee arthroplasty in a Taiwan population. 台湾人群同时与分期双侧全膝关节置换术的安全性与成本分析。
IF 3 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-05-01 DOI: 10.1097/JCMA.0000000000000892
Te-Feng Arthur Chou, Hsuan-Hsiao Ma, Chi-Wu Tsai, Shang-Wen Tsai, Cheng-Fong Chen, Fang-Yao Chiu, Po-Kuei Wu, Wei-Ming Chen

Background: In patients with advanced osteoarthritis (OA) of the bilateral knees, uncertainty remains as to whether simultaneous bilateral total knee arthroplasty (SiTKA) or staged TKA (StTKA) is the treatment of choice. The purpose of this study was to investigate the safety and relative cost of SiTKA vs StTKA in Taiwan patients.

Methods: Using the Big Data Center of Taipei Veterans General Hospital, we retrospectively reviewed all patients who underwent SiTKA or StTKA due to OA or spontaneous osteonecrosis of the knee from January 2011 to December 2016. We assessed length of stay, transfusion rate, early postoperative complications, 30- and 90-day readmission rate, 1-year reoperation rate, and the indication for reoperation. Furthermore, we analyzed the total cost of the two groups, including reimbursement from the national health insurance (NHI), cost of the procedures, and net income from each case.

Results: A total of 2016 patients (1565 SiTKA and 451 StTKA) were included in this study. The two groups had no significant differences in rates of complications, 30- and 90-day readmission, or 1-year reoperation. The length of stay was on average 5.0 days longer for StTKA ( p < 0.01). In terms of cost, all categories of medical costs were significantly lower for SiTKA, while the net hospital income was significantly higher for StTKA.

Conclusion: SiTKA is a safe and cost-effective surgery. Both SiTKA and StTKA have similar rates of postoperative complications, readmission and reoperation, but SiTKA significantly reduces medical expenses for both the patient and the NHI.

背景:在双侧膝关节晚期骨关节炎(OA)患者中,是否选择双侧同期全膝关节置换术(SiTKA)或分期全膝关节置换术(StTKA)仍不确定。本研究的目的是探讨SiTKA与StTKA在台湾患者中的安全性和相对成本。方法:利用台北退伍军人总医院大数据中心,回顾性分析2011年1月至2016年12月所有因OA或自发性膝骨坏死行SiTKA或StTKA的患者。我们评估住院时间、输血率、术后早期并发症、30天和90天再入院率、1年再手术率和再手术指征。此外,我们分析了两组的总成本,包括国民健康保险(NHI)的报销、手术成本和每个病例的净收入。结果:共纳入2016例患者(SiTKA 1565例,StTKA 451例)。两组患者并发症发生率、30天、90天再入院率、1年再手术率无显著差异。StTKA患者住院时间平均延长5.0 d (p < 0.01)。在成本方面,SiTKA的所有类别的医疗费用都明显较低,而StTKA的医院净收入则明显较高。结论:SiTKA是一种安全、经济的手术。SiTKA和StTKA的术后并发症、再入院和再手术率相似,但SiTKA显著降低了患者和国家医疗保健中心的医疗费用。
{"title":"The safety and cost-analysis of simultaneous versus staged bilateral total knee arthroplasty in a Taiwan population.","authors":"Te-Feng Arthur Chou,&nbsp;Hsuan-Hsiao Ma,&nbsp;Chi-Wu Tsai,&nbsp;Shang-Wen Tsai,&nbsp;Cheng-Fong Chen,&nbsp;Fang-Yao Chiu,&nbsp;Po-Kuei Wu,&nbsp;Wei-Ming Chen","doi":"10.1097/JCMA.0000000000000892","DOIUrl":"https://doi.org/10.1097/JCMA.0000000000000892","url":null,"abstract":"<p><strong>Background: </strong>In patients with advanced osteoarthritis (OA) of the bilateral knees, uncertainty remains as to whether simultaneous bilateral total knee arthroplasty (SiTKA) or staged TKA (StTKA) is the treatment of choice. The purpose of this study was to investigate the safety and relative cost of SiTKA vs StTKA in Taiwan patients.</p><p><strong>Methods: </strong>Using the Big Data Center of Taipei Veterans General Hospital, we retrospectively reviewed all patients who underwent SiTKA or StTKA due to OA or spontaneous osteonecrosis of the knee from January 2011 to December 2016. We assessed length of stay, transfusion rate, early postoperative complications, 30- and 90-day readmission rate, 1-year reoperation rate, and the indication for reoperation. Furthermore, we analyzed the total cost of the two groups, including reimbursement from the national health insurance (NHI), cost of the procedures, and net income from each case.</p><p><strong>Results: </strong>A total of 2016 patients (1565 SiTKA and 451 StTKA) were included in this study. The two groups had no significant differences in rates of complications, 30- and 90-day readmission, or 1-year reoperation. The length of stay was on average 5.0 days longer for StTKA ( p < 0.01). In terms of cost, all categories of medical costs were significantly lower for SiTKA, while the net hospital income was significantly higher for StTKA.</p><p><strong>Conclusion: </strong>SiTKA is a safe and cost-effective surgery. Both SiTKA and StTKA have similar rates of postoperative complications, readmission and reoperation, but SiTKA significantly reduces medical expenses for both the patient and the NHI.</p>","PeriodicalId":17251,"journal":{"name":"Journal of the Chinese Medical Association","volume":"86 5","pages":"494-498"},"PeriodicalIF":3.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9882468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A retrospective cohort study on the cardiotoxicity incidence rates of immune checkpoint inhibitors for oncology patients. 肿瘤患者免疫检查点抑制剂心脏毒性发生率的回顾性队列研究。
IF 3 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-05-01 DOI: 10.1097/JCMA.0000000000000910
Chin-Chin Ho, Shang-Liang Wu, Han-Yi Tsai, Yu-Wen Hu, Yuh-Lih Chang

Background: This present study investigated the incidence rates of cardiotoxicity among cancer patients treated with immune checkpoint inhibitors (ICIs) plus other anticancer drugs.

Methods: This was a retrospective hospital-based cohort study using the medical records and the Cancer Registry records from the Taipei Veterans General Hospital. We enrolled patients diagnosed with cancer between 2011 and 2017, who were over 20 years old and had received ICI therapy, including pembrolizumab, nivolumab, atezolizumab, and ipilimumab. Cardiotoxicity was defined by the diagnosis of myocarditis, pericarditis, arrhythmia, heart failure, and Takotsubo syndrome.

Results: We identified 407 patients who were eligible to participate in this study. We defined the three treatment groups as follows: ICI therapy, ICI combined with chemotherapy, and ICI combined with targeted therapy. Using ICI therapy as a reference group, the cardiotoxicity risk was not significantly higher compared to the ICI combined with chemotherapy group (adjusted hazard ratio 2.1, 95% confidence interval 0.2-21.1, p = 0.528] or to the ICI combined with targeted therapy group (adjusted hazard ratio 1.2, 95% confidence interval 0.1-9.2, p = 0.883). The total incidence rate of cardiotoxicity was 3.6 of 100 person-years, indicating an average incidence time of 1.0 ± 1.3 years (median: 0.5 years; range: 0.1-4.7 years) for 18 cardiotoxicity patients.

Conclusion: The incidence rate of ICI-related cardiotoxicity is low. Combination of ICI with either chemotherapy or targeted therapy might not significantly increase the risk of cardiotoxicities among cancer patients. Nevertheless, it is recommend being careful in patients treated high-risk cardiotoxicity medications to avoid drug-related cardiotoxicity with a combination of ICI therapy.

背景:本研究调查了使用免疫检查点抑制剂(ICIs)和其他抗癌药物治疗的癌症患者的心脏毒性发生率。方法:采用台北退伍军人总医院的医疗记录和癌症登记记录,以回顾性医院为基础的队列研究。我们招募了2011年至2017年期间被诊断为癌症的患者,这些患者年龄超过20岁,接受过ICI治疗,包括派姆单抗、纳武单抗、阿特唑单抗和伊匹单抗。心肌炎、心包炎、心律失常、心力衰竭和Takotsubo综合征诊断为心脏毒性。结果:我们确定了407例有资格参加本研究的患者。我们将三个治疗组定义为:ICI治疗、ICI联合化疗、ICI联合靶向治疗。以ICI治疗为参照组,与ICI联合化疗组(校正风险比为2.1,95%可信区间为0.2 ~ 21.1,p = 0.528)或ICI联合靶向治疗组(校正风险比为1.2,95%可信区间为0.1 ~ 9.2,p = 0.883)相比,心脏毒性风险无显著升高。心脏毒性总发生率为3.6 / 100人-年,平均发病时间为1.0±1.3年(中位数:0.5年;范围:0.1-4.7年)18例心脏毒性患者。结论:ci相关心脏毒性发生率较低。ICI联合化疗或靶向治疗可能不会显著增加癌症患者心脏毒性的风险。然而,建议在接受高危心脏毒性药物治疗的患者要小心,以避免与药物相关的心脏毒性与ICI联合治疗。
{"title":"A retrospective cohort study on the cardiotoxicity incidence rates of immune checkpoint inhibitors for oncology patients.","authors":"Chin-Chin Ho,&nbsp;Shang-Liang Wu,&nbsp;Han-Yi Tsai,&nbsp;Yu-Wen Hu,&nbsp;Yuh-Lih Chang","doi":"10.1097/JCMA.0000000000000910","DOIUrl":"https://doi.org/10.1097/JCMA.0000000000000910","url":null,"abstract":"<p><strong>Background: </strong>This present study investigated the incidence rates of cardiotoxicity among cancer patients treated with immune checkpoint inhibitors (ICIs) plus other anticancer drugs.</p><p><strong>Methods: </strong>This was a retrospective hospital-based cohort study using the medical records and the Cancer Registry records from the Taipei Veterans General Hospital. We enrolled patients diagnosed with cancer between 2011 and 2017, who were over 20 years old and had received ICI therapy, including pembrolizumab, nivolumab, atezolizumab, and ipilimumab. Cardiotoxicity was defined by the diagnosis of myocarditis, pericarditis, arrhythmia, heart failure, and Takotsubo syndrome.</p><p><strong>Results: </strong>We identified 407 patients who were eligible to participate in this study. We defined the three treatment groups as follows: ICI therapy, ICI combined with chemotherapy, and ICI combined with targeted therapy. Using ICI therapy as a reference group, the cardiotoxicity risk was not significantly higher compared to the ICI combined with chemotherapy group (adjusted hazard ratio 2.1, 95% confidence interval 0.2-21.1, p = 0.528] or to the ICI combined with targeted therapy group (adjusted hazard ratio 1.2, 95% confidence interval 0.1-9.2, p = 0.883). The total incidence rate of cardiotoxicity was 3.6 of 100 person-years, indicating an average incidence time of 1.0 ± 1.3 years (median: 0.5 years; range: 0.1-4.7 years) for 18 cardiotoxicity patients.</p><p><strong>Conclusion: </strong>The incidence rate of ICI-related cardiotoxicity is low. Combination of ICI with either chemotherapy or targeted therapy might not significantly increase the risk of cardiotoxicities among cancer patients. Nevertheless, it is recommend being careful in patients treated high-risk cardiotoxicity medications to avoid drug-related cardiotoxicity with a combination of ICI therapy.</p>","PeriodicalId":17251,"journal":{"name":"Journal of the Chinese Medical Association","volume":"86 5","pages":"499-505"},"PeriodicalIF":3.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10256225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Comparison of stone-free rate between percutaneous nephrolithotomy and retrograde intrarenal surgery. 经皮肾镜取石术与逆行肾内手术无结石率的比较。
IF 3 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-05-01 DOI: 10.1097/JCMA.0000000000000913
Peng Chen, Tony Tzu-Chun Wei, Eric Yi-Hsiu Huang, Tzu-Ping Lin, Tzu-Hao Huang, Chih-Chieh Lin, I-Shen Huang, William J Huang

Background: The management of urolithiasis in the kidney has been drastically changed in the era of endourology, mainly consisting of three surgical procedures: extracorporeal shock wave lithotripsy (ESWL), percutaneous nephrolithotomy (PCNL), and retrograde intrarenal surgery (RIRS). Since ESWL is usually less invasive via ambulatory clinic routes, this study aimed to examine the stone-free rate (SFR) between PCNL and RIRS.

Methods: We retrospectively reviewed patients who had renal stones and were treated with either PCNL or RIRS from June 2016 to June 2018. Staghorn stones, stones with diameters <1 cm, and stones with diameters >2 cm were excluded. Patients who underwent multiple surgeries for bilateral renal stones and those with graft kidney stones were excluded from the study. X-ray, sonography, and/or computed tomography (CT) were used to calculate the size of the stones. Follow-up was evaluated by the same image examination within three months after surgery. Stone-free was defined as no residual stone or the presence of asymptomatic calculi <4 mm. The operation time was defined as a skin-to-skin interval.

Results: Following exclusion criteria, there were 39 patients in each arm, with no difference in age, sex, or any other demographic data. The average stone size in the PCNL and RIRS groups was 16.3 and 14.0 mm, respectively ( p = 0.009). There was no significant difference in SFR (71.8% vs 61.5%, p = 0.337); the operation time was significant longer ( p < 0.001), and the hospital stay was significantly shorter ( p < 0.001) in the RIRS group.

Conclusion: PCNL and RIRS are both feasible options for managing kidney stones. However, the initial stone size might affect the selection of operation. The SFR in the PCNL group was numerically but not statistically higher. The RIRS group, on the other hand, had a longer operation time but a shorter hospital stays.

背景:肾内尿石症的治疗在泌尿内镜时代发生了巨大的变化,主要包括三种手术方法:体外冲击波碎石术(ESWL)、经皮肾镜取石术(PCNL)和逆行肾内手术(RIRS)。由于ESWL通常通过门诊途径侵入性较小,因此本研究旨在检查PCNL和RIRS之间的无石率(SFR)。方法:我们回顾性分析了2016年6月至2018年6月期间接受PCNL或RIRS治疗的肾结石患者。排除鹿角石、直径2 cm的结石。接受多次手术治疗双侧肾结石和移植肾结石的患者被排除在研究之外。x光、超声和/或计算机断层扫描(CT)被用来计算结石的大小。术后3个月内行相同影像学检查随访。无结石定义为无残留结石或无症状结石的存在。结果:根据排除标准,每组有39例患者,年龄、性别或任何其他人口统计学数据没有差异。PCNL组和RIRS组的平均结石大小分别为16.3和14.0 mm (p = 0.009)。SFR差异无统计学意义(71.8% vs 61.5%, p = 0.337);RIRS组手术时间显著延长(p < 0.001),住院时间显著缩短(p < 0.001)。结论:PCNL和RIRS都是治疗肾结石的可行选择。但是,最初的石材尺寸可能会影响操作的选择。PCNL组的SFR在数值上高于PCNL组,但无统计学意义。另一方面,RIRS组手术时间较长,但住院时间较短。
{"title":"Comparison of stone-free rate between percutaneous nephrolithotomy and retrograde intrarenal surgery.","authors":"Peng Chen,&nbsp;Tony Tzu-Chun Wei,&nbsp;Eric Yi-Hsiu Huang,&nbsp;Tzu-Ping Lin,&nbsp;Tzu-Hao Huang,&nbsp;Chih-Chieh Lin,&nbsp;I-Shen Huang,&nbsp;William J Huang","doi":"10.1097/JCMA.0000000000000913","DOIUrl":"https://doi.org/10.1097/JCMA.0000000000000913","url":null,"abstract":"<p><strong>Background: </strong>The management of urolithiasis in the kidney has been drastically changed in the era of endourology, mainly consisting of three surgical procedures: extracorporeal shock wave lithotripsy (ESWL), percutaneous nephrolithotomy (PCNL), and retrograde intrarenal surgery (RIRS). Since ESWL is usually less invasive via ambulatory clinic routes, this study aimed to examine the stone-free rate (SFR) between PCNL and RIRS.</p><p><strong>Methods: </strong>We retrospectively reviewed patients who had renal stones and were treated with either PCNL or RIRS from June 2016 to June 2018. Staghorn stones, stones with diameters <1 cm, and stones with diameters >2 cm were excluded. Patients who underwent multiple surgeries for bilateral renal stones and those with graft kidney stones were excluded from the study. X-ray, sonography, and/or computed tomography (CT) were used to calculate the size of the stones. Follow-up was evaluated by the same image examination within three months after surgery. Stone-free was defined as no residual stone or the presence of asymptomatic calculi <4 mm. The operation time was defined as a skin-to-skin interval.</p><p><strong>Results: </strong>Following exclusion criteria, there were 39 patients in each arm, with no difference in age, sex, or any other demographic data. The average stone size in the PCNL and RIRS groups was 16.3 and 14.0 mm, respectively ( p = 0.009). There was no significant difference in SFR (71.8% vs 61.5%, p = 0.337); the operation time was significant longer ( p < 0.001), and the hospital stay was significantly shorter ( p < 0.001) in the RIRS group.</p><p><strong>Conclusion: </strong>PCNL and RIRS are both feasible options for managing kidney stones. However, the initial stone size might affect the selection of operation. The SFR in the PCNL group was numerically but not statistically higher. The RIRS group, on the other hand, had a longer operation time but a shorter hospital stays.</p>","PeriodicalId":17251,"journal":{"name":"Journal of the Chinese Medical Association","volume":"86 5","pages":"485-488"},"PeriodicalIF":3.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9880091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Portable sensing devices for smart healthcare and prevention of lead poisoning. 用于智能医疗和预防铅中毒的便携式传感装置。
IF 3 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-05-01 DOI: 10.1097/JCMA.0000000000000904
Wei-Qun Lai, Ta-Chou Huang, Kung-Hao Liang, Yu-Fen Chang, De-Ming Yang

Lead (Pb) poisoning can damage human bodies silently, without specific symptoms or conspicuous warning signs. To provide safe and user-friendly tools for detecting heavy metals at low concentrations, scientists have developed and optimized versatile biosensors. To practically employ the developed biosensors specific for Pb (eg, the optimized Met-lead 1.44 M1), smartphone applications designed for user convenience and are easily operable for the on-site detection of Pb in environmental water, drinking water, food, and blood/urine are urgently needed. To establish a monitoring system for home health maintenance, a portable device and useful apps installed on a smartphone can be integrated, and the data acquired can be sent to and stored in the cloud for further analysis and evidence preservation. With the high transmissions speeds for 4G and 4G wireless Internet, such a system can be applied for health protection; water-quality data can be provided by anyone and publicly shared for display on smartphone interfaces, alerting individuals of heavy metal contamination. In this review, we describe recent developments in heavy metal-sensing devices, including home health maintenance systems, which have been successfully and practically applied to prevent heavy metal Pb poisoning.

铅(Pb)中毒可以悄无声息地损害人体,没有特定的症状或明显的警告迹象。为了提供安全和用户友好的工具来检测低浓度的重金属,科学家们开发并优化了多功能生物传感器。为了实际应用所开发的铅特异性生物传感器(例如,优化的Met-lead 1.44 M1),迫切需要设计方便且易于操作的智能手机应用程序,用于环境水、饮用水、食物和血液/尿液中的铅的现场检测。通过将智能手机上安装的便携设备和有用的应用程序集成在一起,将采集到的数据发送到云端并存储在云端,以便进一步分析和证据保存。该系统具有4G和4G无线互联网的高传输速度,可用于健康保护;任何人都可以提供水质数据,并在智能手机界面上公开共享,提醒人们注意重金属污染。在这篇综述中,我们描述了重金属传感设备的最新进展,包括家庭健康维护系统,这些设备已经成功地和实际地应用于预防重金属铅中毒。
{"title":"Portable sensing devices for smart healthcare and prevention of lead poisoning.","authors":"Wei-Qun Lai,&nbsp;Ta-Chou Huang,&nbsp;Kung-Hao Liang,&nbsp;Yu-Fen Chang,&nbsp;De-Ming Yang","doi":"10.1097/JCMA.0000000000000904","DOIUrl":"https://doi.org/10.1097/JCMA.0000000000000904","url":null,"abstract":"<p><p>Lead (Pb) poisoning can damage human bodies silently, without specific symptoms or conspicuous warning signs. To provide safe and user-friendly tools for detecting heavy metals at low concentrations, scientists have developed and optimized versatile biosensors. To practically employ the developed biosensors specific for Pb (eg, the optimized Met-lead 1.44 M1), smartphone applications designed for user convenience and are easily operable for the on-site detection of Pb in environmental water, drinking water, food, and blood/urine are urgently needed. To establish a monitoring system for home health maintenance, a portable device and useful apps installed on a smartphone can be integrated, and the data acquired can be sent to and stored in the cloud for further analysis and evidence preservation. With the high transmissions speeds for 4G and 4G wireless Internet, such a system can be applied for health protection; water-quality data can be provided by anyone and publicly shared for display on smartphone interfaces, alerting individuals of heavy metal contamination. In this review, we describe recent developments in heavy metal-sensing devices, including home health maintenance systems, which have been successfully and practically applied to prevent heavy metal Pb poisoning.</p>","PeriodicalId":17251,"journal":{"name":"Journal of the Chinese Medical Association","volume":"86 5","pages":"459-464"},"PeriodicalIF":3.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9882478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
An audit of hysterectomy in a teaching hospital in India: Story of a decade. 印度一家教学医院子宫切除术的审计:十年的故事。
IF 3 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-05-01 DOI: 10.1097/JCMA.0000000000000885
Deeksha Pandey, Shripad Hebbar, Pranadeep Reddy Inukollu, Viwal Venisa Lobo, Suvrati Bansal, Divya Solipuram, Nagashree Suhas, Sarah Arsalan Habibullah, Rishi Jitesh Popat, Akshita Agrawal, Sayyad Mg

Background: The appropriateness of hysterectomy has gained an interest in scrutiny and debate. Periodic audits of the prevailing clinical practices are imperative for insight, and to formulate recommendations and guidelines. We report the temporal trends of hysterectomies, over the last 10 years in a teaching hospital.

Methods: Present study involved all patients who underwent hysterectomy at a teaching hospital, from January 1, 2012 to December 31, 2021. Patients were identified by medical record tracking using International Classification of Diseases-9 codes. Case records were reviewed for demography, indication for surgery, approach, complications, hospital stay, and histopathological correlation.

Results: Over the years the absolute number of hysterectomies in our hospital has ranged from 414 to 597 (mean 476), barring the coronavirus 19 pandemic year. The proportion of hysterectomy among all gynaecological admissions has ranged from 6% to 9%, except in 2020 where this proportion dropped down to 4%. The indications, age distribution, surgical approach, and complications have remained almost same.

Conclusion: We report a static trend in hysterectomy over the past 10 years. This audit provides an insight for the need of shifting the abdominal to vaginal route, in carefully chosen patients. This will be beneficial for the patients, and for the trainees, where they can learn under supervision. Availability and patient education about the nonsurgical management options for benign gynecological conditions, as well as awareness about sequelae of hysterectomy, will bring down the rate in countries such as India.

背景:子宫切除术的适当性已经引起了人们的关注和争论。定期审计普遍的临床实践是必要的洞察力,并制定建议和指导方针。我们报告子宫切除术的时间趋势,在过去的10年里,在一家教学医院。方法:本研究纳入2012年1月1日至2021年12月31日在某教学医院接受子宫切除术的所有患者。使用国际疾病分类-9代码通过病历跟踪确定患者。回顾病例记录的人口学、手术指征、入路、并发症、住院时间和组织病理学相关性。结果:除2019冠状病毒大流行年外,我院多年来子宫切除术的绝对数量为414例~ 597例(平均476例)。子宫切除术在所有妇科住院患者中的比例从6%到9%不等,除了2020年,这一比例下降到4%。适应症、年龄分布、手术入路和并发症几乎保持不变。结论:我们报告了过去10年子宫切除术的静态趋势。这个审计提供了一个深入了解需要转移腹部到阴道路线,在精心挑选的病人。这对病人和受训者都是有益的,他们可以在监督下学习。对良性妇科疾病的非手术治疗选择的可用性和患者教育,以及对子宫切除术后遗症的认识,将降低印度等国家的发病率。
{"title":"An audit of hysterectomy in a teaching hospital in India: Story of a decade.","authors":"Deeksha Pandey,&nbsp;Shripad Hebbar,&nbsp;Pranadeep Reddy Inukollu,&nbsp;Viwal Venisa Lobo,&nbsp;Suvrati Bansal,&nbsp;Divya Solipuram,&nbsp;Nagashree Suhas,&nbsp;Sarah Arsalan Habibullah,&nbsp;Rishi Jitesh Popat,&nbsp;Akshita Agrawal,&nbsp;Sayyad Mg","doi":"10.1097/JCMA.0000000000000885","DOIUrl":"https://doi.org/10.1097/JCMA.0000000000000885","url":null,"abstract":"<p><strong>Background: </strong>The appropriateness of hysterectomy has gained an interest in scrutiny and debate. Periodic audits of the prevailing clinical practices are imperative for insight, and to formulate recommendations and guidelines. We report the temporal trends of hysterectomies, over the last 10 years in a teaching hospital.</p><p><strong>Methods: </strong>Present study involved all patients who underwent hysterectomy at a teaching hospital, from January 1, 2012 to December 31, 2021. Patients were identified by medical record tracking using International Classification of Diseases-9 codes. Case records were reviewed for demography, indication for surgery, approach, complications, hospital stay, and histopathological correlation.</p><p><strong>Results: </strong>Over the years the absolute number of hysterectomies in our hospital has ranged from 414 to 597 (mean 476), barring the coronavirus 19 pandemic year. The proportion of hysterectomy among all gynaecological admissions has ranged from 6% to 9%, except in 2020 where this proportion dropped down to 4%. The indications, age distribution, surgical approach, and complications have remained almost same.</p><p><strong>Conclusion: </strong>We report a static trend in hysterectomy over the past 10 years. This audit provides an insight for the need of shifting the abdominal to vaginal route, in carefully chosen patients. This will be beneficial for the patients, and for the trainees, where they can learn under supervision. Availability and patient education about the nonsurgical management options for benign gynecological conditions, as well as awareness about sequelae of hysterectomy, will bring down the rate in countries such as India.</p>","PeriodicalId":17251,"journal":{"name":"Journal of the Chinese Medical Association","volume":"86 5","pages":"506-514"},"PeriodicalIF":3.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9870196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Minimizing the risk of macrosomia. 将巨大儿的风险降到最低。
IF 3 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-05-01 DOI: 10.1097/JCMA.0000000000000901
Szu-Ting Yang, Chia-Hao Liu, Peng-Hui Wang
{"title":"Minimizing the risk of macrosomia.","authors":"Szu-Ting Yang,&nbsp;Chia-Hao Liu,&nbsp;Peng-Hui Wang","doi":"10.1097/JCMA.0000000000000901","DOIUrl":"https://doi.org/10.1097/JCMA.0000000000000901","url":null,"abstract":"","PeriodicalId":17251,"journal":{"name":"Journal of the Chinese Medical Association","volume":"86 5","pages":"536-537"},"PeriodicalIF":3.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9934371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Journal of the Chinese Medical Association
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1